$IRD

2024 Q1 Form 10-K Financial Statement

#000114036124012399 Filed on March 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $1.711M $1.691M $19.05M
YoY Change -2.17% -95.76% -52.2%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.670M $3.279M $11.96M
YoY Change 104.38% 59.64% 64.52%
% of Gross Profit
Research & Development $4.749M $3.841M $17.65M
YoY Change -15.12% 7.11% 22.97%
% of Gross Profit
Depreciation & Amortization $0.00 $6.000K $6.000K
YoY Change -100.0% 500.0% 50.0%
% of Gross Profit
Operating Expenses $9.419M $7.120M $29.61M
YoY Change 19.53% 26.24% 36.94%
Operating Profit -$7.708M -$10.56M
YoY Change 25.72% -157.96%
Interest Expense $0.00 $19.00K $0.00
YoY Change -58.7% -100.0%
% of Operating Profit
Other Income/Expense, Net $602.0K $613.0K $1.837M
YoY Change 77.06% -13221.43%
Pretax Income -$7.106M -$4.797M -$9.974M
YoY Change 22.71% -114.0% -154.79%
Income Tax $0.00 -$2.000K $12.00K
% Of Pretax Income
Net Earnings -$7.106M -$4.795M -$9.986M
YoY Change 22.71% -114.13% -155.83%
Net Earnings / Revenue -415.31% -283.56% -52.42%
Basic Earnings Per Share -$0.29 -$0.46
Diluted Earnings Per Share -$0.29 -$0.21 -$0.46
COMMON SHARES
Basic Shares Outstanding 24.81M 22.64M 21.59M
Diluted Shares Outstanding 24.52M 21.59M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.17M $50.52M $50.52M
YoY Change 20.91% 18.35% 18.35%
Cash & Equivalents $47.20M $50.50M $50.50M
Short-Term Investments $5.000K $15.00K $15.00K
Other Short-Term Assets $89.00K $102.0K $1.099M
YoY Change 14.1% 27.5% -24.36%
Inventory
Prepaid Expenses $1.471M $997.0K
Receivables $1.924M $926.0K $2.333M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $51.84M $53.95M $53.95M
YoY Change 14.2% 10.13% 10.13%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $51.84M $53.95M $53.95M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $51.84M $53.95M $53.95M
YoY Change 14.18% 10.12% 10.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.064M $2.153M $2.153M
YoY Change -7.07% 101.4% 101.4%
Accrued Expenses $3.649M $1.815M $1.815M
YoY Change 88.77% 7.78% 7.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.787M $4.042M $4.042M
YoY Change 39.31% 46.82% 46.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.787M $4.042M $4.042M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.787M $4.042M $4.042M
YoY Change 39.31% 46.82% 46.82%
SHAREHOLDERS EQUITY
Retained Earnings -$88.57M -$81.47M
YoY Change 14.63% 13.97%
Common Stock $3.000K $2.000K
YoY Change 50.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.06M $49.91M $49.91M
YoY Change
Total Liabilities & Shareholders Equity $51.84M $53.95M $53.95M
YoY Change 14.18% 10.12% 10.12%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$7.106M -$4.795M -$9.986M
YoY Change 22.71% -114.13% -155.83%
Depreciation, Depletion And Amortization $0.00 $6.000K $6.000K
YoY Change -100.0% 500.0% 50.0%
Cash From Operating Activities -$5.716M $4.548M -$1.112M
YoY Change 56.77% -84.2% -107.77%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.227M
YoY Change 108.38%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.376M 3.599M 8.979M
YoY Change -30091.67% 137.16%
NET CHANGE
Cash From Operating Activities -5.716M 4.548M -1.112M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 2.376M 3.599M 8.979M
Net Change In Cash -3.340M 8.147M 7.867M
YoY Change -8.39% -71.69% -56.54%
FREE CASH FLOW
Cash From Operating Activities -$5.716M $4.548M -$1.112M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1453000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
15000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
49000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
48986000
CY2023Q4 us-gaap Assets
Assets
53948000
CY2022Q4 us-gaap Assets
Assets
48992000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1069000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1815000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23977491
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23977491
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20861315
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20861315
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131370000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
117717000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71480000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
49906000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
46239000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53948000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48992000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19049000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39850000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11959000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7269000
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17653000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14355000
CY2022 us-gaap Operating Expenses
OperatingExpenses
21624000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-10563000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
18226000
CY2023 us-gaap Interest Expense
InterestExpense
0
CY2022 us-gaap Interest Expense
InterestExpense
9000
CY2023 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
80000
CY2022 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1837000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9974000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18203000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
315000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-9986000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
17888000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2022 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
133000
CY2022 ocup Stock Issued During Period Value Stock Exercise Of Warrants
StockIssuedDuringPeriodValueStockExerciseOfWarrants
0
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1807000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
17888000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
46239000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-9986000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
17888000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3510000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1807000
CY2023 us-gaap Depreciation
Depreciation
6000
CY2022 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-34000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-354000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
139000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1082000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-515000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
123000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-51000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1112000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14314000
CY2023 us-gaap Other Payments To Acquire Businesses
OtherPaymentsToAcquireBusinesses
0
CY2022 us-gaap Other Payments To Acquire Businesses
OtherPaymentsToAcquireBusinesses
0
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8979000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7867000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
18100000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
344000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022 us-gaap Interest Paid Net
InterestPaidNet
9000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
926000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1298000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1099000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
53948000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81466000
CY2023 us-gaap Operating Expenses
OperatingExpenses
29612000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9986000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
17888000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.9
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21589821
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19931080
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21589821
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20597212
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22222000
CY2023 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
136000
CY2023 ocup Stock Issued During Period Value Stock Exercise Of Warrants
StockIssuedDuringPeriodValueStockExerciseOfWarrants
0
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3510000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-9986000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
49906000
CY2022 us-gaap Depreciation
Depreciation
4000
CY2023 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
80000
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-170000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9227000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4428000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
278000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
131000
CY2023 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
538000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3786000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3510000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1807000
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001228627
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-34079
CY2023 dei Entity Registrant Name
EntityRegistrantName
Ocuphire Pharma, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3516358
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
37000 Grand River Avenue, Suite 120
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Farmington Hills
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48335
CY2023 dei City Area Code
CityAreaCode
248
CY2023 dei Local Phone Number
LocalPhoneNumber
957-9024
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
OCUP
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
89224159
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24813370
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
Detroit, Michigan
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50501000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42634000
CY2023Q4 ocup Contract Assets And Unbilled Receivables Current
ContractAssetsAndUnbilledReceivablesCurrent
1407000
CY2022Q4 ocup Contract Assets And Unbilled Receivables Current
ContractAssetsAndUnbilledReceivablesCurrent
3552000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2153000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1684000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
74000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4042000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2753000
CY2023Q4 us-gaap Liabilities
Liabilities
4042000
CY2022Q4 us-gaap Liabilities
Liabilities
2753000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023 ocup Financing Costs
FinancingCosts
1328000
CY2022 ocup Financing Costs
FinancingCosts
0
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.87
CY2022 ocup Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
4428000
CY2023 ocup Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
10249000
CY2023 ocup Financing Costs
FinancingCosts
1328000
CY2022 ocup Financing Costs
FinancingCosts
0
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-372000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1298000
CY2023 ocup Increase Decrease In Contract Assets And Unbilled Receivables
IncreaseDecreaseInContractAssetsAndUnbilledReceivables
-2145000
CY2022 ocup Increase Decrease In Contract Assets And Unbilled Receivables
IncreaseDecreaseInContractAssetsAndUnbilledReceivables
3552000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42634000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24534000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50501000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42634000
CY2023 us-gaap Stock Issued1
StockIssued1
1022000
CY2022 us-gaap Stock Issued1
StockIssued1
0
CY2023 ocup Noncash Or Part Noncash Value Of Derivatives In Connection With Equity Purchase Agreement
NoncashOrPartNoncashValueOfDerivativesInConnectionWithEquityPurchaseAgreement
154000
CY2022 ocup Noncash Or Part Noncash Value Of Derivatives In Connection With Equity Purchase Agreement
NoncashOrPartNoncashValueOfDerivativesInConnectionWithEquityPurchaseAgreement
0
CY2023 ocup Unpaid Issuance Costs
UnpaidIssuanceCosts
10000
CY2022 ocup Unpaid Issuance Costs
UnpaidIssuanceCosts
2000
CY2023 us-gaap Depreciation
Depreciation
6000
CY2022 us-gaap Depreciation
Depreciation
4000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50500000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Use of Estimates</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</div>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Concentration of Credit Risk</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Management follows approved policies established by its Board of Directors to reduce credit risk associated with the Company’s cash deposit and investment accounts. Pursuant to these policies, the Company limits its exposure through the kind, quality and concentration of its investments. The Company’s cash and cash equivalents are held or managed by two financial institutions in the United States. As of December 31, 2023, the Company had cash equivalents of $50.2 million that were not eligible for coverage by Federal Deposit Insurance Corporation (“FDIC”).  These balances are invested in funds whose assets consist almost entirely of securities issued by the U.S. Treasury or guaranteed by the U.S. government.</span></div>
CY2023Q4 ocup Cash Equivalents Not Eligible For Fdic Coverage
CashEquivalentsNotEligibleForFDICCoverage
50200000
CY2023 ocup Impairment On Investment
ImpairmentOnInvestment
0
CY2023 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Derivative Liability</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separation from the underlying agreement under ASC 815 – <span style="font-style: italic;">Derivatives and Hedging</span>. An embedded derivative that requires separation is accounted for as a separate liability from the host agreement.  The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the statements of comprehensive (loss) income under the fair value change in derivative liability line item. The Company determined that certain features under an equity line financing (See Note 8 — Stockholders’ Equity) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying equity line financing agreement.</span></div>
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023 ocup Contingent Value Rights Payment Period
ContingentValueRightsPaymentPeriod
P15Y
CY2020Q4 ocup Percentage Of Cash Consideration Payment
PercentageOfCashConsiderationPayment
0.75
CY2023 ocup Contingent Value Rights Ip Term
ContingentValueRightsIPTerm
P10Y
CY2023Q4 ocup Payments Due Under Cvr Agreement
PaymentsDueUnderCVRAgreement
0
CY2023Q4 ocup Number Of Milestones Accrued
NumberOfMilestonesAccrued
0
CY2021Q2 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2021Q3 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2023 ocup Operating Leases Monthly Base Rent
OperatingLeasesMonthlyBaseRent
3000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
36000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
39000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
36000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
997000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1373000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
102000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
80000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1099000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1453000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
315000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
753000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
782000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
208000
CY2023Q4 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
400000
CY2022Q4 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
212000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
71000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1815000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1684000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
600000
CY2023 ocup Debt Instrument Number Of Installments
DebtInstrumentNumberOfInstallments
6
CY2023Q4 us-gaap Short Term Debt Percentage Bearing Fixed Interest Rate
ShortTermDebtPercentageBearingFixedInterestRate
0.055
CY2022 us-gaap Interest Expense
InterestExpense
9000
CY2023 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
72986
CY2022 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
74396
CY2023 ocup Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
3.77
CY2022 ocup Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
2.04
CY2023 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
275000
CY2022 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
154000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6400000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y9M18D
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21589821
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19931080
CY2023 ocup Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
0
CY2022 ocup Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
589165
CY2023 ocup Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0
CY2022 ocup Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
76967
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21589821
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20597212
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.017
CY2023 ocup Effective Income Tax Benefit Provision Rate Reconciliation At Federal Statutory Income Tax Rate Percent
EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent
-0.21
CY2022 ocup Effective Income Tax Benefit Provision Rate Reconciliation At Federal Statutory Income Tax Rate Percent
EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.238
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.214
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.049
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.049
CY2023 ocup Effective Income Tax Rate Reconciliation Financing Contracts Percent
EffectiveIncomeTaxRateReconciliationFinancingContractsPercent
0.032
CY2022 ocup Effective Income Tax Rate Reconciliation Financing Contracts Percent
EffectiveIncomeTaxRateReconciliationFinancingContractsPercent
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.004
CY2023 ocup Effective Income Tax Rate Reconciliation Research And Development Percent
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentPercent
-0.039
CY2022 ocup Effective Income Tax Rate Reconciliation Research And Development Percent
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentPercent
-0.031
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.019
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.001
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.017
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9974000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18203000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
279000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
10000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
36000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
12000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
315000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
315000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12780000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13087000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
547000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
547000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3794000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2820000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
6000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
7000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
72000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
62000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1835000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1152000
CY2023Q4 ocup Deferred Tax Assets Research And Development
DeferredTaxAssetsResearchAndDevelopment
1107000
CY2022Q4 ocup Deferred Tax Assets Research And Development
DeferredTaxAssetsResearchAndDevelopment
731000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20141000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18406000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20141000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17770000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
636000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
636000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
636000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20100000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18400000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20100000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17800000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
10600000
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
10900000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1100000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
700000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
2100000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
2200000
CY2023Q4 ocup Deferred Tax Assets Tax Credit Carryforwards Research State And Local
DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
0
CY2022Q4 ocup Deferred Tax Assets Tax Credit Carryforwards Research State And Local
DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
0
CY2023 ocup Federal Operating Loss Carryforwards Tax Effect
FederalOperatingLossCarryforwardsTaxEffect
200000
CY2023 ocup State And Local Operating Loss Carryforwards Tax Effect
StateAndLocalOperatingLossCarryforwardsTaxEffect
100000
CY2023 ocup Utilized Federal Research Credit Carryforwards
UtilizedFederalResearchCreditCarryforwards
26000
CY2022 ocup Federal Operating Loss Carryforwards Tax Effect
FederalOperatingLossCarryforwardsTaxEffect
4800000
CY2022 ocup State And Local Operating Loss Carryforwards Tax Effect
StateAndLocalOperatingLossCarryforwardsTaxEffect
1400000
CY2022 ocup Utilized Federal Research Credit Carryforwards
UtilizedFederalResearchCreditCarryforwards
900000
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0001140361-24-012399-index-headers.html Edgar Link pending
0001140361-24-012399-index.html Edgar Link pending
0001140361-24-012399.txt Edgar Link pending
0001140361-24-012399-xbrl.zip Edgar Link pending
ef20015277_10k.htm Edgar Link pending
ef20015277_ex10-5-5.htm Edgar Link pending
ef20015277_ex21-1.htm Edgar Link pending
ef20015277_ex23-1.htm Edgar Link pending
ef20015277_ex31-1.htm Edgar Link pending
ef20015277_ex31-2.htm Edgar Link pending
ef20015277_ex32-1.htm Edgar Link pending
ef20015277_ex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image0.jpg Edgar Link pending
image1.jpg Edgar Link pending
image2.jpg Edgar Link pending
image3.jpg Edgar Link pending
image4.jpg Edgar Link pending
image5.jpg Edgar Link pending
image6.jpg Edgar Link pending
image7.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
ocup-20231231.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
ocup-20231231_cal.xml Edgar Link unprocessable
ocup-20231231_def.xml Edgar Link unprocessable
ocup-20231231_lab.xml Edgar Link unprocessable
ocup-20231231_pre.xml Edgar Link unprocessable
ef20015277_10k_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable